Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Operating Leases: 2019-2025

Historic Operating Leases for Coherus Oncology (CHRS) over the last 7 years, with Sep 2025 value amounting to $1.9 million.

  • Coherus Oncology's Operating Leases fell 47.93% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 47.93%. This contributed to the annual value of $3.3 million for FY2024, which is 38.33% down from last year.
  • Coherus Oncology's Operating Leases amounted to $1.9 million in Q3 2025, which was down 19.12% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Operating Leases peaked at $9.2 million during Q1 2021, and registered a low of $1.4 million during Q3 2023.
  • Over the past 3 years, Coherus Oncology's median Operating Leases value was $3.3 million (recorded in 2024), while the average stood at $3.3 million.
  • As far as peak fluctuations go, Coherus Oncology's Operating Leases plummeted by 76.55% in 2023, and later skyrocketed by 160.24% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Operating Leases stood at $7.3 million in 2021, then plummeted by 30.41% to $5.0 million in 2022, then grew by 5.59% to $5.3 million in 2023, then tumbled by 38.33% to $3.3 million in 2024, then plummeted by 47.93% to $1.9 million in 2025.
  • Its Operating Leases stands at $1.9 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.9 million for Q1 2025.